It can be concluded that more immune cells infiltrating and more activated immune- or inflammation- related pathways as well as higher tumor purity may be the main causes of better prognosis of colon patients in low-risk group, and low-risk patients should be suggested to anti-CTLA4 and anti-LAG3 targeted treatment. The gene discussed is CTLA4; the disease is neoplasm.